Whether the presence of anti-Ro/SS-A antibodies, irrespective of SS, is linked to the future development of LPD remains unclear; however, anti-Ro/SS-A antibodies might be considered as a risk factor for lymphoma in clinical practice. This evidence concerns the gene CALR and disseminated peritoneal leiomyomatosis.